Disruption of mesolimbic regulation of prefrontal cholinergic transmission in an animal model of schizophrenia and normalization by chronic clozapine treatment.
Abnormal mesolimbic control of cortical cholinergic activity has been hypothesized to contribute to the cognitive symptoms of schizophrenia. Stimulation of NMDA receptors in nucleus accumbens (NAC) increases acetylcholine (ACh) release in prefrontal cortex (PFC), an activation thought to contribute to attentional processing. Thus, the effects of intra-NAC perfusion of NMDA (250-400 microM) on ACh release in PFC were determined in rats receiving lesions of the ventral hippocampus (VH) as neonates (nVHLX), a neurodevelopmental model of schizophrenia, or as adults (aVHLX). NMDA elevated ACh release (100-150% above baseline) in adults sham-lesioned as neonates or in aVHLX rats. Adult nVHLX were unresponsive to NAC NMDA receptor stimulation. The inability of nVHLX to respond to NMDA emerged over development as a separate experiment demonstrated that evoked ACh release was normal before puberty (100-150% increase) yet, in these same nVHLX animals, absent after puberty. Amphetamine-evoked ACh release was assessed in nVHLX animals to exclude potential limitations in release capacity. Amphetamine produced greater increases in ACh release than in shams, indicating that nVHLX does not impair the capacity of cholinergic neurons to release ACh. Finally, the ability of 13 days of pretreatment with clozapine (1.25 mg/kg/day) to reinstate NMDA-evoked cortical ACh efflux was determined. Clozapine treatment normalized NMDA-evoked ACh release in nVHLX animals. These experiments show that mesolimbic regulation of cortical ACh release is disrupted in postpubertal nVHLX rats and normalized by low-dose treatment of clozapine; supporting the usefulness of nVHLX animals for research on the neuronal mechanisms underlying the cognitive symptoms of schizophrenia.
Alexander
Kathleen S
KS
Department of Psychology, The Ohio State University, Columbus, OH 43210, USA.
Brooks
Julie M
JM
Sarter
Martin
M
Bruno
John P
JP
D000109:Acetylcholine / Q000378:metabolism*; D000375:Aging; D000661:Amphetamine / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D003024:Clozapine / Q000494:pharmacology*; D004195:Disease Models, Animal; D006624:Hippocampus / Q000503:physiopathology*; D007051:Ibotenic Acid; D008297:Male; D008845:Microinjections; D016202:N-Methylaspartate / Q000008:administration & dosage / Q000494:pharmacology; D009434:Neural Pathways / Q000503:physiopathology*; D009714:Nucleus Accumbens / Q000187:drug effects; D017397:Prefrontal Cortex / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012559:Schizophrenia / Q000139:chemically induced / Q000503:physiopathology*; D013997:Time Factors
D007051:Ibotenic Acid; D016202:N-Methylaspartate; D000661:Amphetamine; D003024:Clozapine; D000109:Acetylcholine
Neuroscience. 2000;96(4):675-85
10727786
Biol Psychiatry. 2004 May 15;55(10):1013-22
15121486
Neuropsychopharmacology. 2007 Oct;32(10):2074-86
17299502
Eur J Neurosci. 2008 Feb;27(3):654-70
18279318
Brain Res. 1992 Jan 20;570(1-2):92-101
1617433
J Neurochem. 2004 Apr;89(2):314-23
15056275
J Neurochem. 1983 Jul;41(1):188-94
6864218
Neurobiol Learn Mem. 2008 Sep;90(2):339-46
18490183
Neuropsychopharmacology. 1996 Dec;15(6):587-94
8946433
Synapse. 2007 Mar;61(3):115-23
17146770
J Neurosci. 1995 May;15(5 Pt 1):3622-39
7751934
Behav Neurosci. 1996 Apr;110(2):247-65
8731052
Pharmacol Ther. 2009 May;122(2):150-202
19269307
Neuropsychopharmacology. 2005 Nov;30(11):1986-95
15900318
Psychopharmacology (Berl). 2009 Jan;202(1-3):237-58
18618100
Brain Res. 1982 May 13;239(2):401-15
6284305
Neuroscience. 2003;122(3):669-76
14622910
Schizophr Res. 2004 Dec 15;72(1):29-39
15531405
Psychopharmacology (Berl). 1995 Nov;122(1):35-43
8711062
Brain Res. 1998 Jun 22;797(1):73-93
9630528
Neuropharmacology. 2007 Sep;53(3):455-63
17681559
Brain Res Cogn Brain Res. 2000 Jun;9(3):313-25
10808142
Neuroscience. 1987 Oct;23(1):103-20
3683859
Am J Psychiatry. 2003 Jan;160(1):118-27
12505810
J Neurosci. 2008 Nov 26;28(48):12691-9
19036962
Schizophr Bull. 2005 Oct;31(4):830-53
16177277
Neuropsychopharmacology. 2008 Oct;33(11):2635-47
18094665
J Chem Neuroanat. 2001 Jul;22(1-2):53-63
11470554
Biol Psychiatry. 2008 Jul 1;64(1):26-33
18549874
Cereb Cortex. 2000 Dec;10(12):1168-75
11073866
Brain Res Brain Res Rev. 2000 Mar;31(2-3):330-41
10719160
Brain Res Brain Res Rev. 2005 Feb;48(1):98-111
15708630
Cereb Cortex. 2006 Jan;16(1):9-17
15788700
Cereb Cortex. 2002 Sep;12(9):975-82
12183396
Schizophr Bull. 1984;10(2):160-203
6729409
J Comp Neurol. 1996 Oct 28;374(4):555-77
8910735
J Chromatogr B Biomed Appl. 1995 Aug 18;670(2):323-7
8548023
Biol Psychiatry. 2004 Jan 15;55(2):172-6
14732597
Eur J Neurosci. 2005 Oct;22(7):1731-40
16197513
Psychopharmacology (Berl). 2004 Nov;176(3-4):312-9
15179541
Synapse. 2009 Mar;63(3):173-80
19086088
J Neurosci. 2002 Mar 1;22(5):1905-13
11880520
J Pharmacol Exp Ther. 2002 Sep;302(3):1135-45
12183673
J Neurosci. 2002 Oct 15;22(20):9070-7
12388614
Brain Res Rev. 2006 Aug;51(2):145-60
16530842
Neuropsychopharmacology. 1993 Aug;9(1):67-75
8397725
Biol Psychiatry. 2006 Sep 15;60(6):585-90
16780812
J Comp Neurol. 1988 Jul 8;273(2):263-82
3417904
Psychopharmacology (Berl). 2004 Jun;174(1):75-85
15118804
Psychopharmacology (Berl). 2004 Jun;174(1):86-98
15071717
Neuropsychopharmacology. 2003 Oct;28(10):1799-809
12784101
J Neurosci. 2004 Feb 4;24(5):1040-9
14762122
Biol Psychiatry. 2007 Oct 1;62(7):730-8
17207473
Neuroscience. 2005;133(2):463-70
15878241
J Pharmacol Exp Ther. 2003 May;305(2):625-31
12606608
Schizophr Bull. 2009 Jan;35(1):109-14
19023126
Schizophr Bull. 2005 Jan;31(1):117-38
15888431
Behav Pharmacol. 2000 Jun;11(3-4):257-68
11103880
Psychophysiology. 1987 Jul;24(4):479-86
3615759
Neuropsychopharmacology. 2002 Mar;26(3):325-39
11850147
Eur J Neurosci. 2003 Jul;18(2):391-402
12887421
Ann N Y Acad Sci. 1999 Jun 29;877:339-67
10415658
Schizophr Res. 2009 Sep;113(2-3):298-307
19500946
Schizophr Bull. 2009 Jan;35(1):182-96
19074499